Therapeutic Immunization against Glioblastoma

@inproceedings{Schijns2018TherapeuticIA,
  title={Therapeutic Immunization against Glioblastoma},
  author={Virgil E.J.C. Schijns and Chrystel Pretto and Anna M Strik and Rianne Gloudemans-Rijkers and Laurent Deviller and Denis Pierre and Jinah Chung and Manisha Ajay Dandekar and Jos{\'e} Aguilera Carrillo and Xiao-Tang Kong and Beverly D Fu and Frank P. K. Hsu and Florence M. Hofman and Thomas C. Chen and Raphael Zidovetzki and Daniela Annenelie Bota and Apostolos Stathopoulos},
  booktitle={International journal of molecular sciences},
  year={2018}
}
Glioblastoma is the most common form of brain cancer in adults that produces severe damage to the brain leading to a very poor survival prognosis. The standard of care for glioblastoma is usually surgery, as well as radiotherapy followed by systemic temozolomide chemotherapy, resulting in a median survival time of about 12 to 15 months. Despite these therapeutic efforts, the tumor returns in the vast majority of patients. When relapsing, statistics suggest an imminent death dependent on the… CONTINUE READING
4
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 38 REFERENCES

Similar Papers

Loading similar papers…